UNSPSC 51393004: Piquizil hydrochloride

This classification denotes a bronchodilator with the molecular formula C19H26N4O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4J5215PFO, chemically known as 4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carboxylic acid isobutyl ester hydrochloride but more generally known as piquizil hydrochloride, which bears US NIH Compound Identifier 192994. Most nations, for tariff and trade purposes, schedule piquizil hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, PIQUIZIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piquizil hydrochloride bears US NLM identifiers UMLS ID C1261482 and NCI Concept Code C90820. SMILES: CC(C)COC(=O)N1CCN(CC1)C2C3CC(C(CC3NCN2)OC)OC.CL.

UNSPSC 51393004 Piquizil hydrochloride is a Commodity code that shows minimal recent alignment with its nominal pharmaceutical scope. The recent opportunities tagged to this code diverge significantly from piquizil itself — one solicitation names naloxone and drug deactivation systems, the other a broad inquiry into direct-to-manufacturer pharmacy benefit administration. Neither represents procurement of piquizil hydrochloride specifically. State and local issuers soliciting under this code appear to be health and human services agencies, with Seminole County, Florida and the Texas Health and Human Services Commission represented in the recent record. The Seminole County opportunity is an IFB for naloxone and safe drug deactivation systems, requiring 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries, posted June 30, 2026, with a July 26, 2023 response date. This code shows little relevant recent activity in piquizil hydrochloride procurement itself.

The geographic footprint is limited to Florida and Texas based on recent records. The Texas Health and Human Services Commission issued a Request for Information (posted April 3, 2026, response deadline April 3, 2026) to explore direct-to-manufacturer prescription programs and vendor capabilities for self-insured pharmacy benefit administration — a market-intelligence exercise rather than a product procurement. The mismatch between the code's pharmaceutical name and the actual work being bought suggests either miscoding of opportunities or a shift in how the category is being applied at the state and local level. Business development professionals should verify code assignment with issuing bodies before investing in pursuit under this Commodity code.